Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth I Ataga

Showing results (1-10 of 133) with videos related to

Pageof 14
Sort By:
Hematology. American Society of Hematology. Education Program|December 17, 2009
Novel therapies in sickle cell diseaseKenneth I Ataga
Clinical Advances in Hematology & Oncology : H&O|August 2, 2018
New and experimental agents for sickle cell diseaseKenneth I Ataga
American Journal of Hematology|April 2, 2026
Natural History of Chronic Kidney Disease in Sickle Cell DiseaseKenneth I Ataga
Blood|October 27, 2023
The challenge of clinical end points in sickle cell diseaseKenneth I Ataga
Haematologica|November 3, 2009
Hypercoagulability and thrombotic complications in hemolytic anemiasKenneth I Ataga
Blood|June 26, 2025
NO (nitric oxide) to priapism with hydroxyurea and tadalafilKenneth I Ataga
Expert Opinion on Investigational Drugs|February 25, 2009
Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemiaKenneth I Ataga, Jonathan Stocker
F1000Research|August 9, 2020
Drug Therapies for the Management of Sickle Cell DiseaseParul Rai, Kenneth I Ataga
British Journal of Haematology|July 1, 2015
The trials and hopes for drug development in sickle cell diseaseKenneth I Ataga, Jonathan Stocker
Ebiomedicine|September 12, 2017
Clinical Implications of the Association of Fetal Hemoglobin with Peripheral Oxygen Saturation in Sickle Cell DiseaseOsheiza Abdulmalik, Kenneth I Ataga
Pageof 14

Showing results (1-10 of 133) with videos related to

Sort By:
Pageof 14
Hematology. American Society of Hematology. Education Program|December 17, 2009
Novel therapies in sickle cell diseaseKenneth I Ataga
Clinical Advances in Hematology & Oncology : H&O|August 2, 2018
New and experimental agents for sickle cell diseaseKenneth I Ataga
American Journal of Hematology|April 2, 2026
Natural History of Chronic Kidney Disease in Sickle Cell DiseaseKenneth I Ataga
Blood|October 27, 2023
The challenge of clinical end points in sickle cell diseaseKenneth I Ataga
Haematologica|November 3, 2009
Hypercoagulability and thrombotic complications in hemolytic anemiasKenneth I Ataga
Blood|June 26, 2025
NO (nitric oxide) to priapism with hydroxyurea and tadalafilKenneth I Ataga
Expert Opinion on Investigational Drugs|February 25, 2009
Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemiaKenneth I Ataga, Jonathan Stocker
F1000Research|August 9, 2020
Drug Therapies for the Management of Sickle Cell DiseaseParul Rai, Kenneth I Ataga
British Journal of Haematology|July 1, 2015
The trials and hopes for drug development in sickle cell diseaseKenneth I Ataga, Jonathan Stocker
Ebiomedicine|September 12, 2017
Clinical Implications of the Association of Fetal Hemoglobin with Peripheral Oxygen Saturation in Sickle Cell DiseaseOsheiza Abdulmalik, Kenneth I Ataga
Pageof 14